LIMINATUS PHARMA INC-CL A (LIMN) Stock Price, Forecast & Analysis
USA - NASDAQ:LIMN - US53271X1081 - Common Stock
LIMN Key Statistics, Chart & Performance
The current stock price of LIMN is 1.165 USD. In the past month the price decreased by -17.38%.
LIMN Latest News, Press Relases and Analysis
LIMN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About LIMN
Company Profile
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Company Info
LIMINATUS PHARMA INC-CL A
6 Centerpointe Dr., #625
La Palma CALIFORNIA US
Employees: 0
Phone: 12132735453
LIMINATUS PHARMA INC-CL A / LIMN FAQ
What does LIMINATUS PHARMA INC-CL A do?
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
What is the current price of LIMN stock?
The current stock price of LIMN is 1.165 USD. The price decreased by -8.98% in the last trading session.
Does LIMN stock pay dividends?
LIMN does not pay a dividend.
How is the ChartMill rating for LIMINATUS PHARMA INC-CL A?
LIMN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Would investing in LIMINATUS PHARMA INC-CL A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LIMN.
Who owns LIMINATUS PHARMA INC-CL A?
You can find the ownership structure of LIMINATUS PHARMA INC-CL A (LIMN) on the Ownership tab.
LIMN Technical Analysis
LIMN Financial Highlights
Over the last trailing twelve months LIMN reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -158.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |